Oncopeptides AB (publ) (ONCO.ST)
SEK 1.75
(4.04%)
SEK 1.75
(4.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -231.62 Million SEK | 27.54% |
| 2022 | -319.61 Million SEK | 77.26% |
| 2021 | -1.39 Billion SEK | 10.85% |
| 2020 | -1.57 Billion SEK | -114.54% |
| 2019 | -734.85 Million SEK | -75.4% |
| 2018 | -419.79 Million SEK | -69.35% |
| 2017 | -247.34 Million SEK | -116.21% |
| 2016 | -114.42 Million SEK | -114.54% |
| 2015 | -53.34 Million SEK | -61.19% |
| 2014 | -33.08 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -65.66 Million SEK | 17.79% |
| 2024 Q2 | -73.25 Million SEK | -12.6% |
| 2023 Q2 | -62.43 Million SEK | 14.17% |
| 2023 FY | - SEK | 27.54% |
| 2023 Q4 | -70.19 Million SEK | -88.21% |
| 2023 Q3 | -37.29 Million SEK | 40.26% |
| 2023 Q1 | -72.74 Million SEK | 17.34% |
| 2022 Q1 | -98.86 Million SEK | 74.61% |
| 2022 FY | - SEK | 77.26% |
| 2022 Q2 | -61.08 Million SEK | 38.21% |
| 2022 Q4 | -87.99 Million SEK | 0.97% |
| 2022 Q3 | -88.85 Million SEK | -45.45% |
| 2021 Q2 | -344.83 Million SEK | 0.72% |
| 2021 Q1 | -347.33 Million SEK | 32.06% |
| 2021 FY | - SEK | 10.85% |
| 2021 Q3 | -338.91 Million SEK | 1.72% |
| 2021 Q4 | -389.34 Million SEK | -14.88% |
| 2020 Q2 | -399.33 Million SEK | -34.51% |
| 2020 FY | - SEK | -114.54% |
| 2020 Q4 | -511.25 Million SEK | -33.31% |
| 2020 Q1 | -296.87 Million SEK | -21.55% |
| 2020 Q3 | -383.49 Million SEK | 3.97% |
| 2019 Q4 | -244.24 Million SEK | -28.82% |
| 2019 Q3 | -189.59 Million SEK | -10.4% |
| 2019 Q2 | -171.73 Million SEK | -40.85% |
| 2019 Q1 | -121.93 Million SEK | -9.64% |
| 2019 FY | - SEK | -75.4% |
| 2018 FY | - SEK | -69.35% |
| 2018 Q4 | -111.21 Million SEK | -7.99% |
| 2018 Q3 | -102.98 Million SEK | 28.02% |
| 2018 Q1 | -68.45 Million SEK | -2.62% |
| 2018 Q2 | -143.07 Million SEK | -109.02% |
| 2017 Q3 | -51.57 Million SEK | 23.32% |
| 2017 FY | - SEK | -116.21% |
| 2017 Q4 | -66.7 Million SEK | -29.34% |
| 2017 Q2 | -67.26 Million SEK | -8.34% |
| 2017 Q1 | -62.08 Million SEK | -21.61% |
| 2016 Q4 | -51.05 Million SEK | -106.96% |
| 2016 FY | - SEK | -114.54% |
| 2016 Q3 | -24.66 Million SEK | -5.04% |
| 2016 Q2 | -23.48 Million SEK | -54.07% |
| 2016 Q1 | -15.24 Million SEK | 0.0% |
| 2015 FY | - SEK | -61.19% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | -427.769% |
| Amniotics AB (publ) | -27.14 Million SEK | -753.34% |
| BioArctic AB (publ) | 275.38 Million SEK | 184.108% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 37.026% |
| Camurus AB (publ) | 562.54 Million SEK | 141.174% |
| Cantargia AB (publ) | -284.31 Million SEK | 18.533% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -1083.012% |
| CombiGene AB (publ) | -35.33 Million SEK | -555.483% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -64.445% |
| Genovis AB (publ.) | 64.57 Million SEK | 458.703% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -101.573% |
| Mendus AB (publ) | -97.84 Million SEK | -136.721% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -525.6% |
| Intervacc AB (publ) | -68.98 Million SEK | -235.781% |
| Kancera AB (publ) | -61.88 Million SEK | -274.254% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -764.81% |
| LIDDS AB (publ) | -39.67 Million SEK | -483.872% |
| Lipum AB (publ) | -37.11 Million SEK | -523.998% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -1813.599% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 837.556% |
| NextCell Pharma AB | -40.98 Million SEK | -465.136% |
| OncoZenge AB (publ) | 7.26 Million SEK | 3287.751% |
| Saniona AB (publ) | -69.69 Million SEK | -232.337% |
| Simris Alg AB (publ) | -22.36 Million SEK | -935.738% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 27.04% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 17.874% |
| Xintela AB (publ) | -53.47 Million SEK | -333.173% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -36.397% |
| Ziccum AB (publ) | -20.34 Million SEK | -1038.639% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -1529.19% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -1255.743% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 11581200.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 2.522% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -11035.673% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -1624.533% |
| Corline Biomedical AB | -1.69 Million SEK | -13597.339% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | -33.635% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -322.622% |
| Aptahem AB (publ) | -10 Million SEK | -2214.085% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 2105.559% |
| Fluicell AB (publ) | -25.91 Million SEK | -793.81% |
| Biovica International AB (publ) | -119.5 Million SEK | -93.816% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -448.555% |
| AcouSort AB (publ) | -16.7 Million SEK | -1286.709% |
| Abliva AB (publ) | -93.6 Million SEK | -147.438% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 27.414% |
| 2cureX AB (publ) | -35.13 Million SEK | -559.216% |
| I-Tech AB | 30.34 Million SEK | 863.295% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 67.585% |
| Cyxone AB (publ) | -20.41 Million SEK | -1034.623% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -126.076% |
| Biosergen AB | 228 Thousand SEK | 101688.596% |
| Nanologica AB (publ) | -62.11 Million SEK | -272.868% |
| SynAct Pharma AB | -222.7 Million SEK | -4.006% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -428.082% |
| BioInvent International AB (publ) | -312.7 Million SEK | 25.93% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 74958.522% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 551594.083% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -2528.341% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -113.362% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -1919.548% |